The DNMT3A Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HAP1 human haploid cell line, designed to disrupt the DNMT3A gene. This heterogeneous pool of edited cells enables loss-of-function studies without the biases of clonal selection, providing a versatile tool to examine DNMT3A??s role in epigenetic regulation.
HAP1 is a near-haploid cell line originating from the KBM-7 chronic myeloid leukemia line, possessing a single copy of most chromosomes. This haploid background simplifies genetic knockout studies because targeting one allele is sufficient to generate functional null phenotypes. HAP1 cells maintain hematopoietic lineage features and are extensively used for genetic screens, drug target validation, and functional genomics due to their robust growth and ease of CRISPR editing.
DNMT3A encodes a de novo DNA methyltransferase that transfers methyl groups from S-adenosylmethionine to cytosines in CpG dinucleotides, establishing methylation marks essential for transcriptional silencing. The enzyme functions in multiprotein complexes with DNMT3L, which stimulates its activity, and recruits HDAC1/2, EZH2, and UHRF1 to reinforce heterochromatin formation. Upstream, DNMT3A is regulated by the OCT4/SOX2/NANOG network, Wnt/??-catenin signaling, and CK2 phosphorylation. Its methylation targets include tumor suppressor genes such as CDKN2A, RASSF1A, SOCS1, and DAPK1, integrating DNMT3A into broader epigenetic circuitry with DNMT1, DNMT3B, and TET dioxygenases.
In the HAP1 haploid context, CRISPR/Cas9-mediated DNMT3A disruption abolishes de novo methylation capacity, potentially reactivating silenced tumor suppressors and perturbing hematopoietic differentiation programs. This knockout is especially relevant for modeling aspects of acute myeloid leukemia and myelodysplastic syndromes, where DNMT3A mutations drive aberrant clonal hematopoiesis. The polyclonal nature captures a spectrum of editing events, allowing assessment of phenotypic heterogeneity and dose-dependent effects in epigenetic regulation.
Applications of this polyclonal knockout model span epigenetic regulation studies, cancer biology, and hematopoiesis research. Representative techniques include bisulfite sequencing for global methylation analysis, RT-qPCR and RNA-seq for gene expression profiling, and proliferation assays coupled with decitabine treatment to evaluate drug sensitivity. The product supports functional dissection of DNMT3A-dependent transcriptional repression and screening of epigenetic therapeutics. For additional information, please contact Ascent Research.
